Australia - English - Department of Health (Therapeutic Goods Administration)

lacorium health australia pty ltd - creatine monohydrate,calcium pantothenate,copper,glutamine,magnesium citrate,nicotinamide,pyridoxine hydrochloride,taurine,thiamine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

thg aus nutrition - creatine monohydrate, quantity: 1 g - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; hypromellose; macrogol 400; povidone; purified water - maintain/support physical endurance/capacity/stamina ; aid/assist muscle growth ; helps enhance/improve/promote/increase muscle strength ; maintain/support muscle strength ; maintain/support muscle performance/endurance/stamina ; aid/assist/helps post exercise recovery ; helps enhance/improve/promote/increase physical/exercise performance

Australia - English - Department of Health (Therapeutic Goods Administration)

emrald labs pty ltd - creatine monohydrate, quantity: 307 mg - pastille - excipient ingredients: citric acid; liquid glucose; sucrose; sorbitol solution (70 per cent) (non-crystallising); sodium benzoate; potassium sorbate; brilliant scarlet 4r; sodium citrate; medium chain triglycerides; carnauba wax; vegetable oil; purified water; flavour - maintain/support energy production ; maintain/support general health and wellbeing ; helps enhance/promote/increase lean body mass ; helps enhance/improve/promote/increase muscle strength ; maintain/support muscle strength ; helps enhance/improve/promote/increase muscle performance/endurance/stamina ; helps enhance/improve/promote/increase physical/exercise performance

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: hypromellose; calcium hydrogen phosphate; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; calcium hydrogen phosphate; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; hypromellose; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; silicon dioxide; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; hypromellose; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: hypromellose; calcium hydrogen phosphate; silicon dioxide; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.